Abstract:BACKGROUND:Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Although there have been substantial improvements in LN treatment over the last decade, the outcome remains unoptimistic in a considerable percentage of patients. The aim of this study was to evaluate the efficacy and safety of mizoribine (MZR), a novel selective inhibitor of inosine monophosphate dehydrogenase, as induction treatment for active LN in comparison with mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC).METHODS:Ninety patients with active LN were observed. Thirty patients were given MZR orally at the dose of 300 mg every other day. Thirty patients took MMF at 2 g per day in two divided doses. Thirty patients received CYC intravenously 0.5 g every 2 weeks. Therapeutic effects and adverse events (AEs) were evaluated at the end of 24-week treatment. One-way analysis of variance (ANOVA) followed by Dunn's test was applied to compare the difference among the groups. For comparing categorical data between two groups, χ(2) test was employed.RESULTS:Early responses at week 12 were achieved by 73.3%, 90.0%, and 96.7% in MZR, MMF, and CYC groups, respectively. There was no significant difference in the complete remission rates (22.7%, 24.0%, and 25.0%, respectively) or overall response rates (68.2%, 72.0%, and 75.0%, respectively) among the three groups at week 24. The most prominent drop-down of Systemic Lupus Erythematosus Disease Activity Index scores was observed in MMF or CYC group, and the decline of health assessment questionnaire scores in MZR or MMF group was more prominent than that in the CYC group at week 12. Serum complement 3 (C3) or C4 levels were elevated in all groups after the treatments. CYC was more effective in inhibiting anti-double-stranded DNA antibody, while MZR was more effective in inhibiting antinuclear antibody. The incidences of AEs in patients treated with CYC were significantly higher than those in patients treated with MZR or MMF (24.2% for CYC vs. 3.3% for MZR, and 2.6% for MMF, P = 0.01).CONCLUSIONS:MZR is well tolerated and has an effect similar to MMF in the induction therapy of active LN. MZR may serve as an alternative approach for LN patients.

Mizoribine Promotes Molecular Chaperone HSP60/HSP10 Complex Formation

Mizoribine and mycophenolate mofetil

Pharmacological action and clinical use of mizoribine

Mizoribine improves renal tubulointerstitial fibrosis in unilateral ureteral obstruction (UUO)-treated rat by inhibiting the infiltration of macrophages and the expression of alpha-smooth muscle actin

Mizoribine: an Effective and Low-Toxic Immunosuppressant for Renal Transplantation Patients

Prospective Trial of Mizoribine Versus Mycophenolate Mofetil in Cyclosporine-based Kidney Transplantation

Therapeutic drug monitoring of mizoribine in renal transplant recipients

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial.

Clinical efficacy of mizoribine in treatment of active systemic lupus erythematosus

Toward Developing Chemical Modulators of Hsp60 as Potential Therapeutics

In vitro antiviral activity of Mizoribine against BK polyomavirus

Mizoribine Versus Mycophenolate Mofetil or Intravenous Cyclophosphamide for Induction Treatment of Active Lupus Nephritis.

Efficacy and Safety of Mizoribine Combined with Losartan in the Treatment of IgA Nephropathy: a Multicenter, Randomized, Controlled Study.

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

Mitsugumin 53 mitigation of ischemia-reperfusion injury in a mouse model

Topical Application of Mizoribine Suppresses CD4+ T-cell-Mediated Pathogenesis in Murine Dry Eye.

Efficacy and Safety of Mizoribine in Comparison with Cyclophosphamide for Treatment of Lupus Nephritis: Protocol for a Multi-Center, Open-Label, Randomized Controlled Trial

HSP90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N 6 -methyladenosine

A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90

Goniothalamin enhances the ATPase activity of the molecular chaperone Hsp90 but inhibits its chaperone activity

Nmi interacts with Hsp105β and enhances the Hsp105β-mediated Hsp70 expression